<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899677</url>
  </required_header>
  <id_info>
    <org_study_id>14893</org_study_id>
    <nct_id>NCT01899677</nct_id>
  </id_info>
  <brief_title>The Efficacy of Symbiotic on Cytokines</brief_title>
  <official_title>The Efficacy of Symbiotic Preparation on Cytokines Which Act on Necrotising Enterocolitis Pathogenesis in Very Low Birth Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective double blinded randomised study is to investigate the efficacy
      of symbiotic preparation which contains lactobacillus casei, L. rhamnosus, L. plantarum,
      Bifidobacterium lactis, fructo and galactooligosaccharide on cytokines as interferon-gama
      acting on Th1 pathway, interleukin -5 acting on Th2, interleukin -10 acting on T regulatory
      pathway,  and interleukin -17 acting on Th-17 pathway that were related with necrotizing
      enterocolitis pathogenesis in very low birth weight neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        1. Neonates who born 26- 32 gestational week and 750-1500 gram birth weights

        2. Neonates who tolerated minimal enteral feeding within postnatal first week

      Exclusion criteria:

        1. PROM&gt; 24 hours and/or chorioamnionitis

        2. Mechanic ventilation supply more than 7 days

        3. Culture proven sepsis

        4. Major congenital anomaly

        5. Patients undergoing surgery

      Intervention:

      The allocations will contain in opaque, sequentially numbered sealed envelopes. The study
      group will receive symbiotic preparation (Probiotic ATP, Nobel,  1/2 sachet twice daily);
      whereas the control group will receive placebo (distilled water; 1 ml per dose twice daily)
      which will be added to breast milk or formula starting with the first feed.0.5 cc blood
      sampling will be taken from patients within postnatal 48 hours, 14+2.days, 28+2.days. This
      samples will turn by cold centrifugation and store at -20 Â°C temperature. The cytokines will
       be analysed by ELISA multiplex method.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Targeted cytokine blood levels via symbiotics</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Necrotising Enterocolitis</condition>
  <arm_group>
    <arm_group_label>symbiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>symbiotic preparation 1/2 sachet twice daily during 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>distilled water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x 0.5 cc distilled water will be given during 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>distilled water</intervention_name>
    <description>0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days</description>
    <arm_group_label>distilled water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>symbiotic</intervention_name>
    <description>Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days</description>
    <arm_group_label>symbiotic</arm_group_label>
    <other_name>Probiotic ATP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Neonates born 26- 32 GWs and 750-1500 gram birth weights

          2. Neonates who tolerated minimal enteral feeding during first week of life

        Exclusion Criteria:

          1. PROM&gt; 24 hour and/or chorioamnionitis

          2. Mechanical ventilation supply more than 7 days

          3. Culture proven sepsis

          4. Major congenital anomaly

          5. Neonates undergoing surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fahri Ovali</last_name>
    <role>Study Director</role>
    <affiliation>Zeynep Kamil Maternity and Childen Education and Training Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ozge Serce</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zeynep Kamil Maternity and Childen Education and Training Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tugba Gursoy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Zeynep Kamil Maternity and Children Education and Training Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fahri Ovali</last_name>
    <email>fovali@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zeynep Kamil Maternity and Child Health Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Umraniye</state>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fahri Ovali, Proff</last_name>
      <phone>+9005324116715</phone>
      <email>fovali@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ozge Serce, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fahri Ovali, Proff</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tugba Gursoy, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Derya Benzer, Specialist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009 Feb;15(2):300-10. doi: 10.1002/ibd.20602. Review.</citation>
    <PMID>18626975</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 12, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zeynep Kamil Maternity and Pediatric Research and Training Hospital</investigator_affiliation>
    <investigator_full_name>Ozge Serce</investigator_full_name>
    <investigator_title>specialist in neonatology</investigator_title>
  </responsible_party>
  <keyword>Symbiotic,cytokines, necrotising enterocolitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
